Investigational Drug Information for ABX464
✉ Email this page to a colleague
What is the drug development status for ABX464?
ABX464 is an investigational drug.
There have been 19 clinical trials for ABX464.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2022.
The most common disease conditions in clinical trials are Colitis, Ulcerative, Colitis, and Ulcer. The leading clinical trial sponsors are Abivax S.A., FLS-RS, and Orion Corporation, Orion Pharma.
There are thirty US patents protecting this investigational drug and six hundred and two international patents.
Summary for ABX464
| US Patents | 30 |
| International Patents | 602 |
| US Patent Applications | 93 |
| WIPO Patent Applications | 42 |
| Japanese Patent Applications | 24 |
| Clinical Trial Progress | Phase 2 (2022-11-01) |
| Vendors | 39 |
Recent Clinical Trials for ABX464
| Title | Sponsor | Phase |
|---|---|---|
| ABTECT - Maintenance | Abivax S.A. | Phase 3 |
| ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 | Abivax S.A. | Phase 3 |
| ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 | Abivax S.A. | Phase 3 |
Clinical Trial Summary for ABX464
Top disease conditions for ABX464
Top clinical trial sponsors for ABX464
US Patents for ABX464
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ABX464 | ⤷ Sign Up | Compounds useful for treating AIDS | ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) | ⤷ Sign Up |
| ABX464 | ⤷ Sign Up | Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13A- octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Sign Up |
| ABX464 | ⤷ Sign Up | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Sign Up |
| ABX464 | ⤷ Sign Up | Human immunodeficiency virus neutralizing antibodies | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| ABX464 | ⤷ Sign Up | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging | ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) | ⤷ Sign Up |
| ABX464 | ⤷ Sign Up | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Sign Up |
| ABX464 | ⤷ Sign Up | Treatments to eliminate HIV reservoirs and reduce viral load | INSTITUT PASTEUR (Paris, FR) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ABX464
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ABX464 | Australia | AU2010258214 | 2029-06-12 | ⤷ Sign Up |
| ABX464 | Australia | AU2010258294 | 2029-06-12 | ⤷ Sign Up |
| ABX464 | Australia | AU2010258295 | 2029-06-12 | ⤷ Sign Up |
| ABX464 | Australia | AU2015203256 | 2029-06-12 | ⤷ Sign Up |
| ABX464 | Australia | AU2017202500 | 2029-06-12 | ⤷ Sign Up |
| ABX464 | Australia | AU2019203896 | 2029-06-12 | ⤷ Sign Up |
| ABX464 | Brazil | BR122019013686 | 2029-06-12 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
